TP53 and cancer: In 2017, Kastenhuber and Lowe [26] discussed the difficulties associated with targeting the p53 network in the context of cancer therapy and concluded that, despite over three decades of intensive research and numerous discoveries, “a clear appreciation of how and in what contexts p53 exerts its diverse effects remains unclear”.